Impact of Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae on the outcome of community-onset bacteremic urinary tract infections.

[1]  Clinical,et al.  Performance standard for antimicrobial susceptibility testing. , 2010 .

[2]  D. Church,et al.  Community-onset extended-spectrum beta-lactamase (ESBL) producing Escherichia coli: importance of international travel. , 2008, The Journal of infection.

[3]  J. Rodríguez-Baño,et al.  Faecal carriage of extended-spectrum beta-lactamase-producing Escherichia coli: prevalence, risk factors and molecular epidemiology. , 2008, The Journal of antimicrobial chemotherapy.

[4]  Samson S. Y. Wong,et al.  CTX-M type beta-lactamases among fecal Escherichia coli and Klebsiella pneumoniae isolates in non-hospitalized children and adults. , 2008, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[5]  A. Apisarnthanarak,et al.  Predictors of Mortality From Community-Onset Bloodstream Infections Due to Extended-Spectrum β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae , 2008, Infection Control & Hospital Epidemiology.

[6]  F. Baquero,et al.  High Rate of Intestinal Colonization with Extended-Spectrum-β-Lactamase-Producing Organisms in Household Contacts of Infected Community Patients , 2008, Journal of Clinical Microbiology.

[7]  G. Simmons,et al.  Extended-spectrum beta-lactamase (ESBL)-producing enterobacteria: factors associated with infection in the community setting, Auckland, New Zealand. , 2008, The Journal of hospital infection.

[8]  K. Laupland,et al.  Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern , 2008 .

[9]  K. Peck,et al.  Clinical features and outcome of community-onset bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli , 2007, European Journal of Clinical Microbiology & Infectious Diseases.

[10]  J. Rodríguez-Baño,et al.  Bacteremia Due to Extended-Spectrum β-Lactamase–Producing Escherichia coli in the CTX-M Era: A New Clinical Challenge , 2006 .

[11]  Clinical,et al.  Performance standards for antimicrobial disk susceptibility tests : approved standard , 2006 .

[12]  J. Rodríguez-Baño,et al.  Epidemiology and Clinical Features of Infections Caused by Extended-Spectrum Beta-Lactamase-Producing Escherichia coli in Nonhospitalized Patients , 2004, Journal of Clinical Microbiology.

[13]  R. Raz,et al.  Risk Factors for the Development of Extended-Spectrum Beta-Lactamase-Producing Bacteria in Nonhospitalized Patients , 2004, European Journal of Clinical Microbiology and Infectious Diseases.

[14]  P. Coll,et al.  Community Transmission of Extended-Spectrum β-Lactamase , 2003, Emerging infectious diseases.

[15]  Daniel J Sexton,et al.  Health CareAssociated Bloodstream Infections in Adults: A Reason To Change the Accepted Definition of Community-Acquired Infections , 2002, Annals of Internal Medicine.

[16]  G. Eliopoulos,et al.  New beta-lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .

[18]  L. Leibovici,et al.  Toward improved empiric management of moderate to severe urinary tract infections. , 1992, Archives of internal medicine.

[19]  G. Jacoby,et al.  More extended-spectrum beta-lactamases , 1991, Antimicrobial Agents and Chemotherapy.

[20]  L. Leibovici,et al.  Bacteremia in febrile patients. A clinical model for diagnosis. , 1991, Archives of internal medicine.

[21]  John E. Bennett,et al.  Principles and practice of infectious diseases. Vols 1 and 2. , 1979 .